Literature DB >> 28912278

Pituitary Macroadenoma and Visual Impairment: Postoperative Outcome Prediction with Contrast-Enhanced FIESTA.

S Hisanaga1, S Kakeda2, J Yamamoto3, K Watanabe1, J Moriya1, T Nagata4, Y Fujino5, H Kondo4, S Nishizawa3, Y Korogi1.   

Abstract

BACKGROUND AND
PURPOSE: Contrast-enhanced FIESTA can depict anterior optic pathways in patients with large suprasellar tumors. We assessed whether the degree of kink in the optic nerve at the optic canal orifice on contrast-enhanced FIESTA correlates with the postoperative improvement of visual impairment in patients with pituitary macroadenoma.
MATERIALS AND METHODS: Thirty-one patients with pituitary macroadenoma who underwent preoperative MR imaging and an operation were evaluated. We measured the optic nerve kinking angle on sagittal oblique contrast-enhanced FIESTA parallel to the optic nerve; the optic nerve kinking angle was defined as the angle between a line parallel to the planum sphenoidale and a line parallel to the intracranial optic nerve at the optic canal orifice. We used logistic regression analyses to determine whether the clinical (sex, age, and duration of symptoms) and imaging (tumor height, chiasmal compression severity, hyperintense optic nerve on T2WI, and optic nerve kinking angle) characteristics were associated with the postoperative improvement (good-versus-little improvement) of visual acuity disturbance and visual field defect.
RESULTS: There were 53 impaired sides before the operation: 2 sides with visual acuity disturbance alone, 25 with visual field defect alone, and 26 with both. After the operation, good improvement was found in 17 of the 28 sides with visual acuity disturbance and in 32 of the 51 sides with visual field defects. Only the optic nerve kinking angle was significantly associated with good improvement of the visual acuity disturbance (P = .011) and visual field defect (P = .002).
CONCLUSIONS: The degree of the optic nerve kinking angle was an independent predictor of postoperative improvement, indicating that irreversible damage to the optic nerve may be associated with its kinking at the optic canal orifice.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2017        PMID: 28912278      PMCID: PMC7963597          DOI: 10.3174/ajnr.A5394

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  23 in total

1.  Evaluation of MR cisternography of the cerebellopontine angle using a balanced fast-field-echo sequence: preliminary findings.

Authors:  Kazuhiro Tsuchiya; Chinatsu Aoki; Junichi Hachiya
Journal:  Eur Radiol       Date:  2003-10-03       Impact factor: 5.315

2.  Delineation of optic nerves and chiasm in close proximity to large suprasellar tumors with contrast-enhanced FIESTA MR imaging.

Authors:  Keita Watanabe; Shingo Kakeda; Junkoh Yamamoto; Rieko Watanabe; Joji Nishimura; Norihiro Ohnari; Shigeru Nishizawa; Yukunori Korogi
Journal:  Radiology       Date:  2012-07-06       Impact factor: 11.105

3.  Identification of the normal jugular foramen and lower cranial nerve anatomy: contrast-enhanced 3D fast imaging employing steady-state acquisition MR imaging.

Authors:  I Davagnanam; S V Chavda
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-07       Impact factor: 3.825

Review 4.  Recovery of vision following transsphenoidal surgery for pituitary adenomas.

Authors:  M Powell
Journal:  Br J Neurosurg       Date:  1995       Impact factor: 1.596

5.  Steady-state free precession imaging in the presence of motion: application for improved visualization of the cerebrospinal fluid.

Authors:  E M Haacke; P A Wielopolski; J A Tkach; M T Modic
Journal:  Radiology       Date:  1990-05       Impact factor: 11.105

6.  Reliability of the Snellen chart.

Authors:  P McGraw; B Winn; D Whitaker
Journal:  BMJ       Date:  1995-06-10

7.  Retinotopic organization of the visual cortex before and after decompression of the optic chiasm in a patient with pituitary macroadenoma.

Authors:  Philippe A Chouinard; Christopher L Striemer; Won Hyung A Ryu; Irene Sperandio; Melvyn A Goodale; David A Nicolle; Brian Rotenberg; Neil Duggal
Journal:  J Neurosurg       Date:  2012-06-08       Impact factor: 5.115

8.  High incidence of optic canal involvement in tuberculum sellae meningiomas: rationale for aggressive skull base approach.

Authors:  Burak Sade; Joung H Lee
Journal:  Surg Neurol       Date:  2009-01-14

Review 9.  Surgical management of acromegaly.

Authors:  R Fahlbusch; J Honegger; M Buchfelder
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

10.  Visual outcome after transsphenoidal surgery for pituitary adenomas.

Authors:  M Peter; N De Tribolet
Journal:  Br J Neurosurg       Date:  1995-04       Impact factor: 1.596

View more
  4 in total

1.  Do We Need Gadolinium-Based Contrast Agents for Routine MRI Surveillance of Unoperated Pituitary Macroadenoma?

Authors:  A A Alali; P B Hanagandi; P J Maralani
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-23       Impact factor: 4.966

2.  Oculomotor nerve palsy in pituitary apoplexy associated with pituitary adenoma: a radiological analysis with fast imaging employing with steady-state acquisition.

Authors:  Yasuo Sasagawa; Hiroyuki Aburano; Kazumasa Ooiso; Masahiro Oishi; Yasuhiko Hayashi; Mitsutoshi Nakada
Journal:  Acta Neurochir (Wien)       Date:  2020-10-31       Impact factor: 2.216

3.  Primary visual cortical thickness in correlation with visual field defects in patients with pituitary macroadenomas: a structural 7-Tesla retinotopic analysis.

Authors:  John W Rutland; Bradley N Delman; Kuang-Han Huang; Gaurav Verma; Noah C Benson; Dillan F Villavisanis; Hung-Mo Lin; Joshua B Bederson; James Chelnis; Raj K Shrivastava; Priti Balchandani
Journal:  J Neurosurg       Date:  2019-10-18       Impact factor: 5.115

4.  Optimizing MR imaging for intraoperative image guidance in sellar pathologies.

Authors:  Alexander Micko; Arthur Hosmann; Wolfgang Marik; Sophie Bartsch; Michael Weber; Engelbert Knosp; Stefan Wolfsberger
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.